Australian family physician · 2004
Guidelines for the management of postmenopausal osteoporosis for GPs.
РекомендацииСтатьяКлинические рекомендацииНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
O'Neill Sheila, MacLennan Alastair, Bass Shona, Diamond Terry, Ebeling Peter, Findlay David, Flicker Leon, Markwell Alex, Nowson Caryl, Pocock Nick, Sambrook Philip, Singh Maria Fiatarone, Osteoporosis Australia Medical Scientific Committee
Аннотация
BACKGROUND: Since the last series of guidelines on the management of osteoporosis from Osteoporosis Australia was published in Australian Family Physician (October 2002), there have been further advances in our understanding of the treatment involved in both the prevention of bone loss and the management of established osteoporosis.
OBJECTIVE: This article provides updated guidelines for the management of postmenopausal osteoporosis to assist general practitioners identify those women at risk, and reviews current treatment strategies.
DISCUSSION: Osteoporosis and its associated problems are major health concerns in Australia, especially with an aging population. While important principles of management are still considered to be maximising peak bone mass and preventing postmenopausal bone loss, new clinical trial data about drugs such as the bisphosphonates, raloxifene and oestrogen have recently become available and the relative role of various agents is gradually becoming clearer. The use of long term hormone therapy has mixed risks and benefits that requires individual patient counselling.
OBJECTIVE: This article provides updated guidelines for the management of postmenopausal osteoporosis to assist general practitioners identify those women at risk, and reviews current treatment strategies.
DISCUSSION: Osteoporosis and its associated problems are major health concerns in Australia, especially with an aging population. While important principles of management are still considered to be maximising peak bone mass and preventing postmenopausal bone loss, new clinical trial data about drugs such as the bisphosphonates, raloxifene and oestrogen have recently become available and the relative role of various agents is gradually becoming clearer. The use of long term hormone therapy has mixed risks and benefits that requires individual patient counselling.
Предметные рубрики MeSH
Absorptiometry, PhotonAgedAntihypertensive AgentsBenzothiadiazinesBiomarkersBone Diseases, MetabolicCalciumDiphosphonatesDiureticsDrug Therapy, CombinationEstrogen Replacement TherapyFamily PracticeFemaleFractures, BoneHumansMiddle AgedOrganometallic CompoundsOsteoporosis, PostmenopausalParathyroid HormoneRisk FactorsSelective Estrogen Receptor ModulatorsSodium Chloride Symporter InhibitorsThiophenesVitamin D